Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[18F]MNI-815 is a radiopharmaceutical positron emission tomography (PET) imaging agent developed as a tau protein tracer for use in the diagnosis and research of Alzheimer's disease and other tauopathies. It is designed to bind selectively to aggregated tau protein in the brain, enabling visualization and quantification of tau pathology via PET imaging. The compound was evaluated in early-phase clinical trials for its potential as a diagnostic tool but was ultimately replaced by more advanced tracers due to suboptimal performance. The primary developer was Molecular NeuroImaging, which later became part of Life Molecular Imaging (formerly Piramal Imaging).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [18F]MNI-815.